CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

Teva’s mAb shows benefit in celiac disease study

Data ReadoutpositivePositive
AI Analysis

Summary

Teva's monoclonal antibody demonstrated benefit in a celiac disease study. Limited details are available in the article regarding trial phase, patient population, or specific efficacy measures.

Clinical Trial Data

Importance:5/10
Sentiment:
0.60
celiac diseasemonoclonal antibodyclinical trialimmunology
Related Companies

Read the original article

Published by yahoo_finance on September 2, 2026 5:22 PM

Read Original